Posted Jun. 18, 2013 at 7:56 p.m.

Premium Lock Dara licenses diabetes compound to new RTP firm with CNS focus

Published: 2013-06-18 19:56:18
Updated: 2013-06-18 19:56:18


Dara BioSciences spent years developing DB959 for diabetes. Now it's been licensed to T3D Therapeutics, which plans to study it in Alzheimer's disease. Read why T3D is a good fit for DB959's new focus....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders